The global fight against obesity is entering a new era. GLP-1 weight-loss medications, including semaglutide and emerging drugs such as retatrutide, are delivering remarkable clinical results. However, alongside their promise, growing concerns about safety, affordability and long-term health are raising important questions.
A breakthrough in childhood obesity
A major development came on November 16, 2026, when Novo Nordisk reported findings from its STEP Young clinical trial, published in The New England Journal of Medicine. The study found that 40.4% of children aged 6 to under 12 with obesity who received semaglutide were no longer classified as having obesity after 68 weeks.
The trial also recorded an average 13.5% reduction in BMI among participants following the treatment regimen. Both groups received lifestyle interventions, including dietary changes and increased physical activity. These findings offer hope in addressing childhood obesity, although long-term safety and appropriate use in younger children remain critical considerations.
Retatrutide raises the stakes
Another promising development is retatrutide, an experimental triple-hormone receptor drug targeting GIP, GLP-1 and glucagon pathways.
Published Phase 3 findings in 2026 reported average weight reductions of up to 25% over 80 weeks in adults with obesity. Separate trial results reported even greater reductions under different study conditions.
However, retatrutide remains investigational, and its impressive results should not be confused with established, approved treatment options.
The hidden cost of rapid weight loss
Rapid weight reduction does not automatically mean improved overall health. Losing weight without adequate nutrition and resistance training can contribute to muscle loss. Preserving lean muscle through sufficient protein intake, strength training and medical supervision is therefore important.
Dosing also matters. Increasing doses without proper medical guidance can increase adverse effects rather than improve outcomes.
Safety and affordability concerns
On November 9, 2026, the US Food and Drug Administration (FDA) announced new safety-label warnings concerning a potential association between GLP-1 medications and non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden vision loss.
Meanwhile, compounded versions of these medications have attracted regulatory scrutiny. The FDA has highlighted concerns involving dosing errors, product quality and inadequate oversight. Affordability and access also remain significant barriers to consistent treatment.
The bigger picture
GLP-1 drugs represent an important advance in obesity management, but they are not magic solutions. Medication must complement sustainable lifestyle changes, proper nutrition and regular medical monitoring.
The real measure of success should not simply be how quickly someone loses weight, but whether they achieve lasting improvements in metabolic health, physical strength and quality of life.
The future of obesity treatment lies not in chasing rapid weight loss, but in making weight management safer, sustainable and accessible.